UBS Group AG Acquires 14,530 Shares of Natera, Inc. (NASDAQ:NTRA)

UBS Group AG lifted its position in shares of Natera, Inc. (NASDAQ:NTRA – Get Rating) by 35.8% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 55,154 shares of the medical research company’s stock after acquiring an additional 14,530 shares during the quarter. UBS Group AG owned approximately 0.06% of Natera worth $2,416,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Ronald Blue Trust Inc. acquired a new position in Natera during the second quarter worth $26,000. Quadrant Capital Group LLC lifted its position in Natera by 4,595.2% during the second quarter. Quadrant Capital Group LLC now owns 986 shares of the medical research company’s stock worth $35,000 after purchasing an additional 965 shares during the period. First Horizon Advisors Inc. raised its stake in Natera by 970.2% during the third quarter. First Horizon Advisors Inc. now owns 1,006 shares of the medical research company’s stock worth $44,000 after acquiring an additional 912 shares in the last quarter. Assetmark Inc. raised its stake in Natera by 50.5% during the third quarter. Assetmark Inc. now owns 1,314 shares of the medical research company’s stock worth $58,000 after acquiring an additional 441 shares in the last quarter. Finally, Wipfli Financial Advisors LLC acquired a new position in Natera during the third quarter worth about $62,000. Institutional investors own 93.81% of the company’s stock.

Insider Activity

In other news, insider Daniel Rabinowitz sold 9,312 shares of the stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $55.96, for a total transaction of $521,099.52. Following the completion of the transaction, the insider now directly owns 175,387 shares of the company’s stock, valued at approximately $9,814,656.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Daniel Rabinowitz sold 9,312 shares of the stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $55.96, for a total transaction of $521,099.52. Following the completion of the transaction, the insider now directly owns 175,387 shares of the company’s stock, valued at approximately $9,814,656.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Michael Burkes Brophy sold 48,697 shares of the stock in a transaction that occurred on Monday, January 30th. The shares were sold at an average price of $42.08, for a total transaction of $2,049,169.76. Following the transaction, the chief financial officer now directly owns 103,990 shares of the company’s stock, valued at $4,375,899.20. The disclosure for this sale can be found here. Insiders sold 189,790 shares of company stock valued at $8,749,687 in the last three months. Company insiders own 10.27% of the company’s stock.

Natera Trading Down 2.4 %

Shares of NTRA stock opened at $56.73 on Tuesday. Natera, Inc. has a 52-week low of $26.10 and a 52-week high of $58.70. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.79 and a current ratio of 3.90. The company has a 50-day simple moving average of $43.71 and a two-hundred day simple moving average of $43.75. The company has a market capitalization of $6.43 billion, a price-to-earnings ratio of -10.18 and a beta of 1.20.

Natera (NASDAQ:NTRA – Get Rating) last issued its quarterly earnings data on Tuesday, February 28th. The medical research company reported ($1.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.40) by $0.03. Natera had a negative net margin of 66.79% and a negative return on equity of 106.67%. The business had revenue of $217.30 million during the quarter, compared to the consensus estimate of $215.50 million. During the same period in the prior year, the firm posted ($1.48) EPS. The firm’s quarterly revenue was up 25.6% compared to the same quarter last year. Research analysts anticipate that Natera, Inc. will post -4.45 EPS for the current fiscal year.

Analyst Ratings Changes

NTRA has been the topic of several recent analyst reports. Robert W. Baird dropped their target price on shares of Natera from $72.00 to $65.00 in a report on Wednesday, November 9th. Stephens dropped their price objective on shares of Natera to $67.00 in a report on Wednesday, November 16th. Morgan Stanley upped their price objective on shares of Natera from $70.00 to $72.00 and gave the company an “overweight” rating in a report on Thursday, March 2nd. Piper Sandler boosted their target price on shares of Natera from $70.00 to $80.00 in a research report on Friday, February 17th. Finally, BTIG Research decreased their target price on shares of Natera from $95.00 to $75.00 in a research report on Wednesday, November 9th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $79.27.

About Natera

(Get Rating)

Natera, Inc is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).